Transformative Merger in Life Sciences & Diagnostics

In an industry-defining move, Waters Corporation (NYSE: WAT) and BD (Becton, Dickinson and Company) (NYSE: BDX) have announced the merger of BD’s Biosciences & Diagnostic Solutions business with Waters. The transaction, valued at approximately $17.5 billion and structured as a tax-efficient Reverse Morris Trust, immediately positions the new entity as a top global player at the crossroads of life science, regulated diagnostics, and high-volume laboratory automation.

The combined company is expected to generate approximately $6.5 billion in pro forma revenue in 2025, with an adjusted EBITDA of around $2.0 billion. Notably, over 70% of revenue will be recurring—reflecting robust demand for consumables, instruments, and support across clinical and research laboratories worldwide.

Doubling Market Reach and Creating Shareholder Value

Waters’ total addressable market (TAM) is set to double to approximately $40 billion, with market growth rates projected at 5–7% annually, thanks to the combined forces of the two companies. The merger brings together Waters’ expertise in liquid chromatography and mass spectrometry with BD’s market-leading capabilities in flow cytometry, molecular diagnostics, and clinical solutions.

Shareholders can expect a rapid impact: the deal is forecast to deliver about $345 million in annualized EBITDA synergies by 2030, including $200 million in cost savings within three years and $290 million in revenue synergies within five years. Performance projections indicate mid-to-high single-digit annual revenue growth and mid-teens adjusted EPS growth, with the transaction accretive to Waters’ earnings per share within the first year post-closing.

Waters and BD’s boards of directors unanimously approved the agreement, highlighting the deal’s strategic merits and clear opportunity for value creation.

Strategic Benefits and Market Expansion

• Complementary Technology Portfolios: The combined company will lead in high-volume, regulated testing end-markets, blending Waters’ analytic technologies with BD’s strengths in diagnostics and laboratory automation.
• Enhanced Recurring Revenue Base: More than 70% of annual revenue is projected to be recurring, providing a stable operating foundation and facilitating continual investment in research and development.
• High-Growth Market Entry: The new business will accelerate entry into high-velocity sectors such as bioseparations (critical for biologics manufacturing), bioanalytical characterization, and precision molecular diagnostics. Increasing regulatory requirements and global health challenges have driven laboratories to shift toward higher testing throughput and automation—an area where the merged company stands to benefit strongly.

This unified platform is anticipated to enhance customer offerings—using Waters’ Empower™ informatics for data management and BD’s extensive reach in clinical and academic settings to unlock substantial cross-selling potential across consumables, instruments, and software.

Financial Highlights and Synergy Targets

The merged company will create a behemoth in diagnostics and analytical sciences:

• Revenue (2025E): $6.5 billion (pro forma)
• Adjusted EBITDA (2025E): $2.0 billion
• Synergies by 2030: $345 million, including both cost and revenue synergies
• Projected Revenue by 2030: $9 billion, with an adjusted operating margin of 32%
• EPS Accretion: Expected immediately in the first year after completion

Cost savings are expected primarily from improved supply chain management, optimized manufacturing, and streamlined SG&A (selling, general, and administrative) expenses. Revenue growth is anticipated from accelerated innovation, e-commerce expansion, and broader adoption of service contracts.

For 2025, BD’s Biosciences & Diagnostic Solutions will contribute an estimated $3.4 billion in revenue and $925 million in adjusted EBITDA, reinforcing the financial strength of the integration.

Deal Structure and Timeline

The transaction uses a Reverse Morris Trust structure, enabling tax efficiency. BD shareholders will own around 39.2% of the combined entity, while Waters shareholders will hold 60.8%. BD will receive approximately $4 billion in cash before the deal closes and plans to use at least half for share repurchases, with the balance allocated to debt reduction.

Waters will assume about $4 billion in new debt, resulting in a pro forma net-debt-to-adjusted EBITDA leverage ratio of 2.3x. Leadership will remain strong, with Dr. Udit Batra, current CEO of Waters, leading the new company and key executives from both legacy organizations in pivotal roles. The headquarters will stay in Milford, Massachusetts, with a continued significant presence in current BD locations.

Closing is expected by the end of Q1 2026, pending regulatory and shareholder approvals.

Industry and Market Outlook

This union comes amid rapidly rising demand for regulated, high-throughput testing in clinical, pharmaceutical, and research settings. Global molecular diagnostics markets alone are forecast to grow from $24.1 billion in 2022 to $38 billion by 2028 (CAGR: ~8%). Lab automation, multiplex diagnostics, and biologics manufacturing all face increased scrutiny, throughput mandates, and innovation pressure—conditions that strongly favor companies with broad portfolios and robust R&D pipelines.

Waters and BD have both invested heavily in data management solutions, AI-powered diagnostic analytics, sample preparation, and workflow automation. The combined company will be poised to meet surging demand for precision medicine, cancer diagnostics, and pandemic preparedness, while leveraging a global footprint and deep regulatory expertise.

Industry analysts have responded positively to the transaction, citing its potential to accelerate global access to advanced testing, improve patient outcomes through more robust diagnostics, and deliver meaningful cost savings to laboratory customers coping with budget pressures and rising test volumes.

Leadership Commentary

Dr. Flemming Ornskov, Chairman, Waters: “This transaction marks a pivotal milestone in Waters’ transformation. The strategic alignment and combined expertise will create tremendous new value for stakeholders across healthcare, clinical diagnostics, and life sciences.”

Dr. Udit Batra, CEO, Waters: “We are combining pioneering teams with strong innovation heritage and customer focus. The opportunities for growth across bioseparations, molecular diagnostics, and analytics are tremendous.”

Tom Polen, CEO, BD: “Combining complementary portfolios allows us to serve high-growth end-markets with breakthrough innovation and operational excellence. Our legacy in global healthcare will thrive within this new organization.”

Advisors and Additional Resources

Barclays and Kirkland & Ellis advised Waters, while Citi, Evercore, and Wachtell, Lipton, Rosen & Katz counseled BD. Investors and stakeholders are encouraged to follow developments via Waters’ and BD’s investor relations portals and the dedicated transaction microsite at combination.waters.com.

For investor questions, contact Waters IR, or check the SEC filings for detailed financial disclosures and regulatory updates.